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Objectives This study sought to develop a risk score predictive of bleeding in patients undergoing percuta-
neous coronary intervention (PCI) and to investigate the impact of bleeding on subsequent mortality.
Background Bleeding complications after PCI have been independently associated with early and
late mortality.
Methods This study represents a patient-level pooled analysis including 17,034 patients undergoing PCI
from 3 large, randomized trials of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors, including
the REPLACE-2 (Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events), ACUITY
(Acute Catheterization and Urgent Intervention Triage Strategy), and HORIZONS-AMI (Harmonizing Out-
comes With Revascularization and Stents in Acute Myocardial Infarction) trials. We developed a risk score
to predict noncoronary artery bypass graft (CABG)–related TIMI (Thrombolysis In Myocardial Infarction) major
bleeding and evaluated the impact of various types of bleeding on 1-year mortality.
Results A non-CABG–related TIMI major bleed occurred within 30 days in 267 patients (1.6%), and
death occurred in 497 patients (2.9%) within 1 year. A risk score was developed to predict the bleeding
risk of patients undergoing PCI, consisting of 7 variables (serum creatinine, age, sex, presentation, white
blood cell count, cigarette smoking, and randomized treatment). The TIMI major bleeding rates increased
by bleeding risk score groups: from 0.4% for those in the lowest to 5.8% for those in the highest risk
group. Non-CABG–related TIMI major bleeding and the occurrence of myocardial infarction within 30
days were independent predictors of subsequent mortality, with respective hazard ratios of 4.2 and 2.9,
each p  0.001. Ranked in order of severity, TIMI major bleeding, blood transfusion without TIMI bleed,
TIMI minor bleeding requiring blood transfusion, and TIMI minor bleeding not requiring blood transfu-
sion were independent predictors of subsequent mortality with hazard ratios of 4.89, 2.91, 2.73, and 1.66,
respectively. Isolated hematomas were not predictive of subsequent mortality.
Conclusions Non-CABG–related bleeding within 30 days is strongly associated with an increased
risk of subsequent mortality at 1 year in patients undergoing PCI for all indications. A risk score was
established to calculate the bleeding risk for patients undergoing PCI, allowing therapeutic decision
making to minimize the incidence of bleeding. (J Am Coll Cardiol Intv 2011;4:654–64) © 2011 by
the American College of Cardiology Foundation
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655The use of multiple antithrombotic drugs along with early
invasive strategies has increased the risk of bleeding in
patients with acute coronary syndrome (ACS) and in those
undergoing percutaneous coronary intervention (PCI) (1–4).
Recent studies have shown that bleeding complications have
been consistently and independently associated with adverse
clinical outcomes, including myocardial infarction (MI),
stroke, and death (4–10). Major bleeding is associated with
a 2- to 8-fold increase in subsequent mortality in ACS (5–7)
and PCI (4–6,8–10). The increase in hazard of death
among patients who develop major bleeding is equivalent to
or greater than that for those who develop MI (11,12).
Notably, the association between bleeding and mortality
appears to have a monotonic relationship, that is, increasing
severity of bleeding is associated with an increased risk of
death (5,13,14).
We recently developed a risk score to predict the rate of
noncoronary artery bypass graft (CABG)–related bleeding in
ACS patients based upon a pooled analysis of the large-scale
multicenter ACUITY (Acute Catheterization and Ur-
gent Intervention Triage Strategy Trial) (15) and
HORIZONS-AMI (Harmonizing Outcomes With Re-
vascularization and Stents in Acute Myocardial Infarction)
(16) trials (13). However, this previous analysis had 2 major
limitations that limit its applicability to predict bleeding after
PCI: 1) only ACS patients were included; and 2) a large
proportion of patients were treated medically or surgically.
To develop a simple-to-use risk score to identify patients
undergoing PCI who are at increased risk for bleeding, we
now report an analysis from a pooled database of 17,034
patients undergoing PCI in the ACUITY, HORIZONS-
AMI (Harmonizing Outcomes With Revascularization and
Stents in Acute Myocardial Infarction), and REPLACE-2
(Randomized Evaluation in PCI Linking Angiomax to
Reduced Clinical Events) (17) trials. The latter trial prin-
cipally enrolled patients with stable ischemic heart disease
undergoing PCI. We sought to develop a risk score appli-
cable across the spectrum of coronary artery disease risk (i.e.,
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cardial infarction [STEMI], and non-STEMI), which may
allow personalized decision making to select therapies and
subsequently improve clinical outcomes in a broad cross
section of patients.
Methods
This study represents a patient-level pooled analysis of PCI
patients from 3 large, randomized trials of bivalirudin versus
heparin plus glycoprotein IIb/IIIa inhibitors (GPI): the
REPLACE-2 trial in stable and unstable ischemic syn-
dromes, the ACUITY trial in unstable angina and non-
STEMI, and HORIZONS-AMI trial in patients with
STEMI. The design and principal results of each trial have
been published previously (15–19). In brief, in the
REPLACE-2 trial, 6,010 patients undergoing elective or
urgent PCI were randomized to heparin plus a GPI (abcix-
imab or eptifibatide) or bivaliru-
din with provisional GPI use.
Provisional GPI with either ab-
ciximab or eptifibatide could be
administered for procedural or
angiographic complications in
the bivalirudin group. All pa-
tients received aspirin, and pre-
treatment with clopidogrel with
daily administration for at least
30 days after intervention was
strongly encouraged.
In ACUITY, 13,819 patients
with moderate- and high-risk
ACS were randomly assigned to
1 of 3 antithrombotic regimens
before cardiac catheterization:
a heparin (unfractionated or
enoxaparin) plus a GPI, bivalirudin plus a GPI, or bivali-
rudin monotherapy, in which GPI administration was
Johnson & Johnson, and The Medicines Company. Dr. White has received research
grants from Sanofi-Aventis; Eli Lilly, The Medicines Company, NIH, Pfizer, Roche,
Johnson & Johnson, Schering-Plough, Merck Sharpe & Dohme, AstraZeneca, Glaxo-
SmithKline, Daiichi Sankyo Pharma Development, and Bristol-Myers Squibb; and he
has received a consultancy fee from Regado Biosciences. Dr. Bertrand has received
consulting fees from Servier Laboratories, Sanofi-Aventis, and Nycomed; and lecture fees
from Servier Laboratories and Sanofi-Aventis. Dr. Lansky has received research grants
from The Medicines Company, Cordis, Boston Scientific, Medtronic, and Abbott. Dr.
Ohman received research grants from Daiichi Sankyo, Eli Lilly and Co., and Maquet; and
received consulting fees from Roche, AstraZeneca, Boehringer Ingelheim, Bristol-Myers
Squibb, Liposcience, Merck, Pozen, Inc., Sanofi-Aventis, The Medicines Company,
Gilead Sciences, and WebMD. Dr. Lincoff has received research grants from Bristol-
Myers Squibb, Kai, Roche, Pfizer, Schering/Merck, and Takeda; and is a consultant for
Schering/Merck, Bioline, Bristol-Myers Squibb, Baxter, and Roche. Dr. Stone is
consultant to Merck, Eli Lilly, AstraZeneca, The Medicines Company, Abbott Vascular,
Boston Scientific, Medtronic, and Bristol-Myers Squibb/Sanofi. All other authors have
reported that they have no relationships to disclose.
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
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656permitted only for bail-out indications (15,18). All patients
received aspirin, and timing and dosing of clopidogrel was
left to the discretion of investigators and treating physicians.
The details of the dosing and timing of the study medica-
tions has been previously described (15,18).
In HORIZONS-AMI, 3,602 patients with STEMI who
presented within 12 h after symptom onset in whom primary
PCI was planned were randomly assigned to treatment with
unfractionated heparin plus a GPI or to bivalirudin mono-
therapy (16,19). Aspirin and clopidogrel (either 300 mg or 600
mg, at the discretion of the investigator), or ticlopidine (500
mg in the case of allergy to clopidogrel) was administered
before catheterization (16,19).
For the purpose of the current analysis, only those
patients were selected who actually underwent PCI as their
primary treatment and who did not have a TIMI (Thrombol-
ysis In Myocardial Infarction) major bleed before the index
PCI (REPLACE-2: n  5,902, ACUITY: n  7,783,
ORIZONS-AMI: n  3,349, combined: n  17,034). All
rimary and secondary endpoints of the 3 trials including major
leeding were adjudicated by a blinded clinical events commit-
ee. Bleeding was adjudicated as related or not related to the
erformance of CABG. Only major bleeding complications
djudicated as unrelated to CABG are included in the current
nalysis. In the REPLACE-2 trial, major bleeding was defined
s intracranial, intraocular, or retroperitoneal hemorrhage;
linically overt blood loss resulting in a decrease in hemoglobin
f more than 3 g/dl; any decrease in hemoglobin of more than
g/dl; or transfusion of 2 or more units of packed red blood
ells or whole blood. In HORIZONS-AMI and ACUITY,
he definition of major bleeding included all the above, plus
ccess site hemorrhage requiring intervention and hematoma
5 cm at the puncture site. Moreover, any blood product
ransfusion was regarded as a major bleeding. For the purpose
f the current analysis, using detailed clinical and laboratory
ata, overall major bleeding was classified in a hierarchy from
evere to mild as TIMI major bleeding, blood transfusion with
o TIMI bleed, TIMI minor bleeding with blood transfusion,
IMI minor bleeding without blood transfusion, or isolated
arge hematoma (5 cm). The TIMI bleeding definition has
een published in detail previously (20). Likewise, the defini-
ion of MI in the REPLACE-2, ACUITY, and
ORIZONS-AMI trials have been published in detail previ-
usly (15–17).
The REPLACE-2, ACUITY, and HORIZONS-AMI
rials were conducted according to the Declaration of
elsinki and were approved by the institutional review
oard or ethics committee at each participating center. For
ach study, all patients provided written informed consent.
Statistical analysis. The databases of the REPLACE-2,
ACUITY, and HORIZONS-AMI trials were combined,
and from these, the univariate associations of 20 baseline
variables and randomized treatment with non-CABG–
related TIMI major bleeding within 30 days and death Twithin 1 year were determined. A forward stepwise logistic
regression model was used to identify the independent
predictor TIMI major bleeding within 30 days; p  0.1 was
the criterion for inclusion in the final model. The logistic
model predictor was converted to a more user-friendly
integer score predicting an individual’s probability of
bleeding within 30 days. Having grouped each quantita-
tive factor into convenient categories (e.g., 10-year age
group), an individual’s score increases by an integer
amount for each level above the lowest category. Each
integer amount is a rounding of the exact figure obtained
from the logistic model. A 0 score indicates a person at
very low risk: for example, a man under 50 years of age with
the lowest-risk category of each other predictor. Because the
effect of randomized treatment is assessed subsequently, the
integer risk score first assumes the patient received heparin
plus a GPI.
The model’s goodness of fit was assessed by calculating
the risk score for every patient, and categorizing these scores
into 4 categories from low risk to very high risk. The actual
observed percentage with a TIMI major bleeding in each
category was compared with the expected percentage, the
latter being the sum of the individual predicted probabilities
from the logistic model.
To investigate the impact of TIMI major bleeding and
MI on the occurrence and timing of subsequent mortality,
baseline and randomized treatment-adjusted Cox models
were fitted with each adverse event as a time-updated binary
covariate (21). To estimate the time-dependent risk on mor-
tality of TIMI major bleeding and MI, the Cox models were
extended to have different time-updated binary covariates for
different time intervals, that is, days 0 to 1, days 2 to 7, days 8
to 30, and days 31 post-event. Further models then intro-
duced covariates for 5 different types of bleeding: TIMI
major bleeding, TIMI minor bleeding with blood trans-
fusion, blood transfusion with no TIMI bleed, TIMI
minor bleeding without blood transfusion, and large
hematoma only (5 cm). Each bleeding was assigned to
its most severe category. All analyses were carried out
using Stata (version 10.1, StataCorp, College Station,
Texas). All significance levels are 2-sided. All statistical
data analyses were performed at an independent data-
coordinating center, separate from the clinical coordinat-
ing and data coordinating centers of the 3 trials. The
authors had full access to the data and take responsibility
for its integrity. All authors have read and agree to the
manuscript as written.
Results
Incidence and predictors of non-CABG–related bleeding. Among
7,041 patients undergoing PCI in the 3 trials, 7 patients
ere excluded for the current analysis as they experienced a
IMI major bleed before their index PCI. Among the
; UFH/E
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657remaining 17,034 patients, a TIMI major bleed occurred
within 30 days of randomization in 43 of 5,902 (0.7%)
REPLACE-2 patients, 137 of 7,783 (1.8%) ACUITY
patients, and 87 of 3,349 (2.6%) HORIZONS-AMI
patients. Within 1 year after randomization, death had
occurred in 124 (2.1%) REPLACE-2 patients, 239
Table 1. Baseline Characteristics
Total*
Study REPLACE-2
ACUITY
HORIZONS-AMI
Presentation† Normal biomarkers (Elective/ACS)
Raised biomarkers (NSTEMI)
STEMI
ACS‡ No ACS
ACS
STEMI
Treatment UFH/Enox  GPI
Bivalirudin alone
Bivalirudin  GPI
Age, yrs
Sex Male
Female
Weight, kg
Ethnic groups Caucasian
Other
Diabetic status Any
None
Noninsulin diabetes
Insulin-requiring diabetes
Current cigarette smoker
Hypertension
Previous MI
Previous PCI
Previous CABG
Serum creatinine, mg/dl
n 2.5 mg/dl
CrCl, ml/min
n 250 ml/min
Hematocrit, %
Hemoglobin, g/dl
Anemia§
Platelet count, g/dl
White blood cell count, 109/l
n 20 109/l
Values are n, mean SD, n (%), ormedian (interquartile range). *Excludes 7 patients (0 deaths) unde
‡ACS in non-STEMI patients. Note all HORIZONS-AMI patients were included as STEMI presentation
ACS acute coronary syndrome(s); ACUITY Acute Catheterization and Urgent Intervention Tr
GPI  glycoprotein IIb/IIIa inhibitor; HORIZONS-AMI  Harmonizing Outcomes With Revasculariz
elevation myocardial infarction; PCI  percutaneous coronary intervention; REPLACE-2  Rando
myocardial infarction; TIMI Thrombolysis In Myocardial Infarction; UFH unfractionated heparin(3.1%) ACUITY patients, and 134 (4.0%) HORIZONS-AMI patients. Table 1 displays baseline characteristics
for all patients included in the current analysis, those
with 30-day TIMI major bleeding, and those with 1-year
mortality in the combined REPLACE-2, ACUITY, and
HORIZONS-AMI trials.
Multivariable analysis selected 6 baseline demographic
tal Number of
Patients
TIMI Major Bleeding Within
30 Days
Death Within
1 Year
17,034 267 (1.6%) 497 (2.9%)
5,902 43 (0.7%) 124 (2.1%)
7,783 137 (1.8%) 239 (3.1%)
3,349 87 (2.6%) 134 (4.0%)
6,626 69 (1.0%) 144 (2.2%)
5,206 102 (2.0%) 175 (3.4%)
3,349 87 (2.6%) 134 (4.0%)
4,551 33 (0.7%) 102 (2.2%)
9,134 147 (1.6%) 261 (2.9%)
3,349 87 (2.6%) 134 (4.0%)
7,178 135 (1.9%) 225 (3.1%)
7,249 71 (1.0%) 189 (2.6%)
2,607 61 (2.3%) 83 (3.2%)
62.2 11.4 66.6 12.1 70.5 10.7
12,668 168 (1.3%) 337 (2.7%)
4,366 99 (2.3%) 160 (3.7%)
85.6 17.8 81.5 18.2 80.1 18.3
15,587 239 (1.5%) 448 (2.9%)
1,439 28 (1.9%) 49 (3.4%)
4,283 82 (1.9%) 187 (4.4%)
12,691 184 (1.4%) 308 (2.4%)
3,073 56 (1.8%) 116 (3.8%)
1,210 26 (2.1%) 71 (5.9%)
5,450 98 (1.8%) 128 (2.3%)
10,771 173 (1.6%) 356 (3.3%)
4,829 71 (1.5%) 170 (3.5%)
5,391 65 (1.2%) 158 (2.9%)
2,538 34 (1.3%) 112 (4.4%)
00 (0.84–1.14) 1.10 (0.90–1.30) 1.10 (0.90–1.40)
73 (0.4) 4 (1.6) 14 (3.0)
89 (67–114) 74 (49–99) 64 (47–82)
45 (0.3) 0 (0.0) 1 (0.2)
41 5 41 7 39 6
14.0 1.6 13.8 2.0 13.3 2.0
2,818 64 (2.3%) 154 (5.5%)
237 67 250 82 245 90
.1 (6.5–10.3) 9.2 (7.3–12.0) 9.3 (7.3–12.6)
15 (0.7) 10 (3.8) 14 (3.0)
PCI who experienced a TIMImajor bleed before the procedure. †Biomarkers in non-STEMI patients.
: hemoglobin13 g/dl; Women: hemoglobin12 g/dl.
ategy Trial; CABG coronary artery bypass graft; CrCl creatinine clearance; Enox enoxaparin;
d Stents in Acute Myocardial Infarction; MI  myocardial infarction; NSTEMI  non–ST-segment
Evaluation of PCI Linking Angiomax to Reduced Clinical Events; STEMI  ST-segment elevation
nox GPI unfractionated heparin or enoxaparin plus a glycoprotein IIb/IIIa inhibitor.To
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658independent predictors of TIMI major bleeding within 30
days (Table 2): elevated serum creatinine, advanced age,
female sex, presentation (by normal biomarkers [elective/
ACS], raised biomarkers [non-STEMI], and STEMI),
elevated white blood cell count, current cigarette smoking,
and randomized treatment (heparin  GPI as compared
ith bivalirudin monotherapy [in REPLACE-2, ACUITY,
nd HORIZONS-AMI] and bivalirudin  GPI as com-
ared with bivalirudin monotherapy [in ACUITY]) (model
-statistic  0.74). The integer risk score derived from this
odel appears in Figure 1. It consists of the summation of
integers (1 from each baseline variable) that represent the
ndividual risk of bleeding if the patient received heparin 
GPI. If bivalirudin is administered instead, 6 points are
ubtracted from the integer score. Figure 2 shows the risk
istribution and the predicted probability of a bleeding in
ll 17,034 patients for each integer score assuming they
ere on heparin  a GPI. From observation of these
ata, 4 categories for bleeding risk may arbitrarily be
efined: low, moderate, high, and very high correspond-
ng to integer scores 10, 10 to 14, 15 to 19, and 20,
espectively. Table 3 shows the observed incidence of
0-day TIMI major bleeding, overall major bleeding, and
ts individual components in these 4 risk categories. When
ompared with heparin  a GPI, bivalirudin monotherapy
esulted in less 30-day TIMI major bleeding in patients
ith moderate (0.5% vs. 1.3%), high (1.2% vs. 2.6%), and
ery high risk (2.8% vs. 5.8%).
Non-CABG–related bleeding and mortality. Table 4 presents
the multivariable Cox model relating deaths within 1 year
(n  497 [2.9%] of 17,034 patients) in the combined
REPLACE-2/ACUITY/HORIZONS-AMI database to
independent baseline predictors. We identified 9 indepen-
dent predictors of 1-year mortality, of which advanced age,
Table 2. Independent Predictors of Non-CABG–Related TIMI Major Bleedin
Risk Factor
Serum creatinine Per 0.1 mg/dl
Age Per 5 yrs
Sex Male
Female
Presentation Normal biomarkers (Elective/ACS)
NSTEMI – raised biomarkers
STEMI
White blood cell count Per 109/l
Current cigarette smoker No
Yes
Randomized treatment UFH/Enox  GPI
Bivalirudin alone
Bivalirudin  GPI
*Intercept8.97. †Absolute value of z score1.96, 2.58, 3.29, 3.89, 4.42 corresponds to p value
CI confidence interval; other abbreviations as in Table 1.elevated white blood cell count and serum creatinine,reduced hemoglobin, and diabetes were the most strongly
related. In this model, bivalirudin monotherapy as com-
pared with unfractionated heparin  GPI was associated
with a decreased risk of mortality (hazard ratio [HR]: 0.82),
whereas bivalirudin  GPI therapy and unfractionated
heparin  GPI had an identical risk (HR: 1.00).
When added to this multivariate model as time-
updated covariates, both the occurrence of TIMI major
bleeding and the occurrence of MI within 30 days were
independent predictors of subsequent mortality, with
respective HRs of 4.2 and 2.9, each p  0.001 (Fig. 3).
A difference in the temporal relationship between the
impact of these variables on mortality was noted, how-
ever. Following occurrence of MI, the mortality risk
declined over time, whereas following a TIMI major
bleeding, the associated mortality increase remained sig-
nificantly elevated even beyond 30 days.
Table 5 displays the hierarchical incidence of 5 types of
non-CABG–related bleeding within 30 days, ranked in
order of severity (from greatest to least) as TIMI-defined
major bleeding, transfusion with no TIMI bleed, TIMI
minor bleeding with transfusion, TIMI minor bleeding
without transfusion, and large hematoma only. Figure 4
shows the relationship between the severity of 5 types of
non-CABG–related bleeding and subsequent mortality.
TIMI major bleeding was an independent predictor of
subsequent mortality with an HR of 4.89. TIMI minor
bleeding requiring a blood transfusion or a transfusion
with no TIMI bleed had an almost 3-fold increased
hazard of mortality, whereas TIMI minor bleeding not
requiring transfusion nearly doubled the risk of subse-
quent mortality. In contrast, development of a hematoma
5 cm without more severe bleeding indexes was not a
in 30 Days, Using Multiple Logistic Regressions
s Ratio 95% CI Coefficient* z Score†
1.12 1.09–1.16 0.117 6.87
1.21 1.14–1.29 0.190 5.92
1.00 — — —
1.77 1.36–2.31 0.57 4.23
1.00 — — —
1.49 1.08–2.05 0.40 2.40
2.16 1.50–3.12 0.77 4.15
1.08 1.03–1.12 0.073 3.64
1.00 — — —
1.67 1.25–2.24 0.51 3.43
1.00 — — —
0.50 0.37–0.67 0.70 4.70
1.34 0.96–1.88 0.29 1.70
.01, 0.001, 0.0001, 0.00001, respectively.g With
Odd
0.05, 0statistically significant predictor of subsequent mortality.
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659Discussion
This patient-level pooled analysis demonstrates that across a
broad spectrum of patients with coronary artery disease
undergoing PCI: 1) the occurrence of TIMI major bleeding
within 30 days is strongly associated with an increased risk
of subsequent mortality at 1 year, even more so than the risk
arising from a periprocedural MI; 2) a simple risk model can
be created from 6 baseline demographic and laboratory
variables and 1 treatment-related variable that is strongly
predictive of TIMI major bleeding within 30 days in
patients undergoing PCI; and 3) the risk of subsequent
mortality depends on the type of bleeding, which ranked
in decreasing order of severity—TIMI major bleeding,
transfusion with no TIMI bleed, TIMI minor bleeding
with transfusion, and TIMI minor bleeding without
transfusion—are associated with an increased risk of
mortality at 1-year follow-up, whereas an isolated large
Figure 1. Integer-Based Risk Score for Non-CABG–Related TIMI Major Blee
For a patient who has a creatinine of 1.3 mg/dl, is 72 years of age, is fema
infarction (NSTEMI) without raised biomarkers, and is a nonsmoker, her risk
chance of a noncoronary artery bypass graft (CABG)–related TIMI (Thrombo
patient is treated with bivalirudin alone rather than heparin  a glycoprot
indicating a 1.4% chance of a non-CABG–related TIMI major bleed within 3
tion myocardial infarction.hematoma was not.Quantifying risk in relation to clinically meaningful
events has always been a challenge for clinical research
studies. Our initial observations that have compared the
relative prognostic impact of MI and periprocedural bleed-
ing have shown that both events are associated with an
increased risk for mortality (11,22). In the present study, we
increased the sample size by merging 3 datasets of large-
sized contemporary multicenter randomized clinical trials
and used individual patient data elements to construct a risk
score for bleeding for patients undergoing PCI, either
elective or emergent. Our current analysis has shown that
the risk conveyed by a bleeding event indeed pertains to
early as well as late mortality (Fig. 3). Additionally, it
appears that the risk for subsequent mortality conferred by
a MI event is much stronger in the peri-MI period, but
fades over time, more quickly than the risk conferred by
bleeding.
We then sought to determine what type of bleeding
ithin 30 Days of PCI
s a white cell count of 11 109/l, has non–ST-segment elevation myocardial
would be: 4  9  5  1  0  0  19 total score, signifying a 2.7%
n Myocardial Infarction) major bleed within 30 days (see Fig. 2). If the
/IIIb inhibitor (GPI), the total score should be reduced by 6 to 13 points,
s. PCI  percutaneous coronary intervention; STEMI  ST-segment eleva-ding W
le, ha
score
lysis I
ein IIa
0 daywould best correlate with mortality. We subdivided all
from t
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660non-CABG–related bleeding into 5 bleeding types and
documented that short of an isolated hematoma (even when
large-sized), all other types of bleeding were independent
predictors of subsequent mortality. Interestingly, bleeding
that required transfusion, but did not meet the criteria for a
TIMI bleed (HR: 2.91), conferred a similar risk of subse-
quent mortality as a TIMI minor bleed requiring transfu-
sion (HR: 2.73). Recently, an analysis by the STEEPLE
(Safety and Efficacy of Enoxaparin in Percutaneous Coro-
nary Intervention patients: An International Randomized
Figure 2. Distribution of the Integer Risk Score and Consequent Probabilit
Distribution of the integer risk score and consequent probability of a non-CAB
rin  GPI). For patients treated with bivalirudin monotherapy, 6 points should
patients treated with bivalirudin monotherapy, 6 points should be subtracted
Table 3. Incidence of Bleeding by 30 Days Stratified by Risk Category
Type of Bleed*
<10
(n  5,346) (n
TIMI major 33 (0.6)
TIMI minor with blood transfusion 29 (0.5)
Blood transfusion without TIMI bleed 14 (0.3)
TIMI minor without blood transfusion 88 (1.6)
Large hematoma only 59 (1.1)
Overall major bleeding including hematoma 166 (3.1)
Overall major bleeding without hematoma 108 (2.0)
Values are n (%) or n/N (%). *TIMI bleedwith/without transfusion relates to the event status at 30 day
or transfusion at 30 days. †The denominator excludes those with each type of bleed before percutTIMI Thrombolysis In Myocardial Infarction.Evaluation) investigators also showed no relationship be-
tween hematomas5 cm and clinical outcome after elective
PCI, which is consistent with the observations in the
current analysis (14). Previous studies have also suggested
that bleeding is associated with an increased risk of recur-
rent ischemic events, longer hospital stay, and increased cost
(11,23,24). Although a causal link between bleeding and
adverse outcome has not been established, there are several
potential mechanisms linking bleeding with an increased
risk of ischemic events (1,3,10), including discontinuation
Non-CABG–Related TIMI Major Bleed Within 30 Days of PCI
ted TIMI major bleed within 30 days of PCI (assuming treatment with hepa-
btracted from the score. Assuming treatment with heparin  a GPI. For
he score. Abbreviations as in Figure 1.
Risk Category
Total†
4
90)
15–19
(n  3,835)
>20
(n  2,063)
.0) 78 (2.0) 99 (4.8) 267/17,034 (1.6)
.8) 53 (1.4) 84 (4.1) 215/17,001 (1.3)
.7) 60 (1.6) 83 (4.0) 195/17,001 (1.1)
.8) 151 (3.9) 108 (5.3) 509/17,001 (3.0)
.5) 45 (1.2) 31 (1.5) 224/17,020 (1.3)
.3) 253 (6.6) 282 (13.8) 952/16,996 (5.6)
.0) 215 (5.6) 258 (12.6) 756/17,009 (4.4)
hematomaonly relates towhether the patient experienced the event in the absence of a TIMI bleed
coronary intervention.y of a
G–rela
be su10–1
 5,7
57 (1
49 (0
38 (0
162 (2
89 (1
251 (4
175 (3
s. Large
aneous
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661of antithrombotic drugs in patients who suffer bleeding
complications (25,26), the direct effects of blood transfusion
with stored red cells used to treat bleeding (3,27), or greater
prevalence of comorbidities in patients who bleed (25).
Other unknown factors such as intraplaque hemorrhage due
to long-term use of dual antiplatelet therapy may also be
involved. Balancing the anti-ischemic benefits against the
potential bleeding risk of long-term use (1 year) of dual
antiplatelet therapy also warrants further study.
When determining which patients undergoing PCI will
benefit the most from more aggressive antiplatelet and
antithrombotic therapy, it is important to assess the risk of
bleeding complications. Currently, several bleeding risk
models have been proposed. The CRUSADE (Can Rapid
Risk Stratification of Unstable Angina Patients Suppress
Adverse Outcomes With Early Implementation of the
ACC/AHA Guidelines) bleeding score was developed and
validated in 89,000 community-treated non-STEMI pa-
tients that included those undergoing initial invasive strat-
egy and revascularization and those conservatively managed
without catheterization (28). Similar to the CRUSADE
bleeding score, the present study found that female sex and
lower creatinine clearance were independent predictors of
bleeding. The other variables identified in this report to
increase bleeding differ from the CRUSADE analysis.
However, the CRUSADE investigators limited their anal-
ysis to non-STEMI patients, of whom almost half did not
undergo PCI. Moreover, because a large number of vari-
Table 4. Independent Predictors of 1-Year Mortality From Multivariable Co
Risk Factor
Age Per 5 yrs
White blood cell count Per 109/l
Serum creatinine Per 0.1 mg/dl
Hemoglobin Per g/dl
Diabetic status No diabetes
Noninsulin dependent
Insulin dependent
Presentation Normal biomarkers (elective/ACS)
Raised biomarkers (NSTEMI)
STEMI
Current smoker No
Yes
Previous CABG No
Yes
Previous MI No
Yes
Randomized treatment UFH/Enox  GPI
Bivalirudin alone
Bivalirudin  GPI
*Absolute value of z score1.96, 2.58, 3.29, 3.89, 4.42 corresponds to p value0.05, 0.01, 0.001, 0.0
Abbreviations as in Tables 1 and 2.ables were missing in the CRUSADE database, the patientswith a complete dataset, upon which the CRUSADE risk
score was derived, represent a highly selected sample.
Furthermore, follow-up of CRUSADE patients was limited
to in-hospital events.
Mehta et al. (2) recently proposed a bleeding risk score
based upon an analysis of 302,152 PCI procedures from the
NCDR (National Cardiovascular Data Registry). Although
they investigated a very large number of patients who
underwent PCI for a broad range of indications, the NCDR
bleeding definition differs from the most commonly used
bleeding definitions, such as the TIMI definition used in
the current paper. Moreover, no analysis was performed to
identify whether bleeding according to the NCDR defini-
tion is associated with a higher mortality rate.
The current bleeding risk score for patients undergoing
PCI is similar but not identical to the risk score we
recently proposed for ACS patients based upon an
analysis from the pooled ACUITY and HORIZONS-
AMI trials (13). In this previous analysis, only ACS
patients were included, and a large proportion of these
patients were not treated with PCI, but rather were
managed medically or surgically. The current risk score is
designed to predict the risk of a non-CABG–related
TIMI major bleed, whereas the previous model predicted
for a broader range of bleeding definitions (TIMI major
bleed, transfusion without TIMI bleed, and TIMI minor
bleed). We decided to focus on TIMI major bleeding,
because this bleeding definition has the most significant
ression
rd Ratio 95% CI Coefficient z Score*
1.40 1.33–1.47 0.335 13.37
1.16 1.13–1.19 0.145 10.87
1.09 1.06–1.11 0.082 6.82
0.84 0.79–0.88 0.179 6.39
1.00 — — —
1.38 1.11–1.72 0.32 2.94
1.70 1.30–2.23 0.53 3.86
1.00 — — —
1.31 1.04–1.66 0.27 2.32
1.63 1.24–2.15 0.49 3.50
1.00 — — —
1.43 1.14–1.80 0.36 3.04
1.00 — — —
1.40 1.11–1.76 0.33 2.86
1.00 — — —
1.32 1.08–1.61 0.28 2.75
1.00 — — —
0.82 0.67–0.99 0.20 2.02
1.00 0.77–1.31 0.00 0.00
00001, respectively.x Reg
Haza
001, 0.clinical impact. Moreover, we showed that even in
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662patients with a modest risk of TIMI major bleeding (risk
scores: 10 to 14), there was an important risk for other
types of clinically significant bleeding (transfusion with-
out TIMI bleed, TIMI minor bleed). In the previous, but
not in the current risk score, baseline anemia was a
predictor of bleeding, whereas current smoking is a
predictor of bleeding in the current model. Moreover, the
integer values for the individual components of the risk
score have been updated in the current model to accu-
Figure 3. Independent Hazard of the Occurrence of TIMI Non-CABG–Relate
Within 1 Year
Independent hazard of the occurrence of TIMI non-CABG–related major bleed
line predictors. Note that 45 patients had both a TIMI major bleed and an MI
models in Figure 3 have time-updated covariates for both events. Adjusted fo
abbreviations as in Figure 1.
Table 5. Hierarchical Incidence of Non-CABG–Related Bleeding Within 30 D
REPLACE-2 (n  5,894)
TIMI major bleed 43 (0.7)
Transfusion with no TIMI bleed 49 (0.8)
Transfusion with TIMI minor bleed 30 (0.5)
TIMI minor bleed without blood transfusion 92 (1.6)
Large hematoma only† 100 (1.7)
Total 314 (5.3)
Values are n (%). Patients are represented only once according to their most severe bleed. *Exclu
transfusion or other component of study defined major bleed.Abbreviations as in Table 1.rately predict the bleeding risk for patients undergoing
PCI.
We believe that the current risk score is practical (vari-
ables are readily available) and has documented prognostic
importance. We showed that bivalirudin monotherapy was
associated with lower bleeding rates and mortality. The
greatest absolute reduction in bleeding with bivalirudin was
seen among patients in the highest bleeding risk category.
Therefore, the use of bivalirudin in patients at high risk of
or Bleed and of MI Within 30 Days on Subsequent Mortality
f MI within 30 days on subsequent mortality within 1 year, adjusted for base-
30 days, and 11 of those patients died within 1 year. For such patients, the
line predictors. CI  conﬁdence interval; MI  myocardial infarction; other
TY (n  7,746) HORIZONS-AMI (n  3,349) Total (n  16,989*)
133 (1.7) 87 (2.6) 263 (1.5)
46 (0.6) 20 (0.6) 115 (0.7)
73 (0.9) 23 (0.7) 126 (0.7)
300 (3.9) 91 (2.7) 483 (2.8)
76 (1.0) 14 (0.4) 190 (1.1)
628 (8.1) 235 (7.0) 1,177 (6.9)
tients with any bleed before the PCI. †Large hematoma refers to a patient without a TIMI bleed,d Maj
and o
within
r baseays
ACUI
ding pa
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663bleeding would be expected to have the greatest impact on
survival. A recent cost-effectiveness study by Amin et al.
(29) suggested that bivalirudin, as opposed to unfraction-
ated heparin, would be cost-effective in patients with a
bleeding risk of 5%. Furthermore, several studies suggest
that radial as opposed to femoral arterial access is associated
with reduced rates of bleeding and vascular complications, with
similar rates of procedural success when performed by experi-
enced operators (30,31). As the greatest absolute effect of radial
versus femoral access, however, is to decrease hematomas,
these 2 approaches may have comparable survival.
Study limitations. This is a post hoc analysis of a pooled
dataset of randomized controlled trials and, therefore,
should be considered hypothesis-generating. Despite ad-
justment for potential confounders, unmeasured variables
may not have been controlled for, and data to prove a causal
relation between bleeding events, MI, and death cannot be
established. The results of the current analysis may only be
applied to PCI patients. Thus, our results and proposed risk
model of bleeding cannot be extrapolated to patients man-
aged either medically or surgically. None of the patients in
this large pooled dataset was treated with heparin mono-
therapy; therefore, this risk score is not applicable to
patients undergoing PCI with heparin monotherapy. More-
over, the use of novel antiplatelet agents such as prasugrel
and ticagrelor may affect the bleeding risk of patients
undergoing PCI. Despite the large sample size of the
present study, given the wide confidence interval around the
hazard for isolated hematomas (HR: 1.43, 95% confidence
interval: 0.64 to 3.21), an effect of hematomas on subse-
quent survival cannot be totally excluded. Only a very small
proportion of patients in the current pooled dataset were
treated with radial access; therefore, we were unable to
assess the influence of the radial approach on the incidence
of bleeding or survival. Finally, external validation of this
Figure 4. Independent Hazard of the Occurrence of Different Types of Majo
Independent hazard of the occurrence of different types of major bleed within
Abbreviations as in Figures 1 and 3.risk score in another dataset is warranted. Nonetheless, thepresent study represents a very robust, patient-based analysis
across a broad spectrum of patients undergoing PCI, for
whom data were prospectively collected and all adverse
events were adjudicated by independent observers blinded to
treatment group.
Conclusions
The present analysis demonstrates that the occurrence of a
non-CABG–related bleed occurring within 30 days after
PCI is associated with an increased risk of subsequent
mortality through 1 year of follow-up. In order of severity,
TIMI major bleeding, transfusion without TIMI bleed,
TIMI minor bleeding with transfusion, and TIMI minor
bleeding without transfusion were all independent predic-
tors of mortality. The strength of the current risk score,
derived from this large-scale patient-level pooled database
lies in its applicability to patients undergoing PCI for all
indications and can guide medical decision making to
prevent bleeding.
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